<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://hmg.oxfordjournals.org">
<title>Human Molecular Genetics - current issue</title>
<link>http://hmg.oxfordjournals.org</link>
<description>Human Molecular Genetics - RSS feed of current issue</description>
<prism:eIssn>1460-2083</prism:eIssn>
<prism:coverDisplayDate>1 December 2009</prism:coverDisplayDate>
<prism:publicationName>Human Molecular Genetics</prism:publicationName>
<prism:issn>0964-6906</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-a?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-b?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-c?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4467?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4478?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4492?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4501?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4513?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4521?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4530?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4546?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4552?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4565?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4576?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4590?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4603?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4615?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4629?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4640?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4650?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4662?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4669?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4677?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4688?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP?rss=1">
<title><![CDATA[Contents Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp485</dc:identifier>
<dc:title><![CDATA[Contents Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-a?rss=1">
<title><![CDATA[Cover Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp486</dc:identifier>
<dc:title><![CDATA[Cover Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-b?rss=1">
<title><![CDATA[Editorial Board]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-b?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp487</dc:identifier>
<dc:title><![CDATA[Editorial Board]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-c?rss=1">
<title><![CDATA[Subscription Page]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/NP-c?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp488</dc:identifier>
<dc:title><![CDATA[Subscription Page]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4467?rss=1">
<title><![CDATA[Ku70 regulates Bax-mediated pathogenesis in laminin-{alpha}2-deficient human muscle cells and mouse models of congenital muscular dystrophy]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4467?rss=1</link>
<description><![CDATA[
<p>The severely debilitating disease Congenital Muscular Dystrophy Type 1A (MDC1A) is caused by mutations in the gene encoding laminin-2. Bax-mediated muscle cell death is a significant contributor to the severe neuromuscular pathology seen in the <I>Lama2</I>-null mouse model of MDC1A. To extend our understanding of pathogenesis due to laminin-2-deficiency, we have now analyzed molecular mechanisms of Bax regulation in normal and laminin-2-deficient muscles and cells, including myogenic cells obtained from patients with a clinical diagnosis of MDC1A. In mouse myogenic cells, we found that, as in non-muscle cells, Bax co-immunoprecipitated with the multifunctional protein Ku70. In addition, cell permeable pentapeptides designed from Ku70, termed Bax-inhibiting peptides (BIPs), inhibited staurosporine-induced Bax translocation and cell death in mouse myogenic cells. We also found that acetylation of Ku70, which can inhibit binding to Bax and can be an indicator of increased susceptibility to cell death, was more abundant in <I>Lama2</I>-null than in normal mouse muscles. Furthermore, myotubes formed in culture from human laminin-2-deficient patient myoblasts produced high levels of activated caspase-3 when grown on poly-<scp>l</scp>-lysine, but not when grown on a laminin-2-containing substrate or when treated with BIPs. Finally, cytoplasmic Ku70 in human laminin-2-deficient myotubes was both reduced in amount and more highly acetylated than in normal myotubes. Increased susceptibility to cell death thus appears to be an intrinsic property of human laminin-2-deficient myotubes. These results identify Ku70 as a regulator of Bax-mediated pathogenesis and a therapeutic target in laminin-2-deficiency.</p>
]]></description>
<dc:creator><![CDATA[Vishnudas, V. K., Miller, J. B.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp399</dc:identifier>
<dc:title><![CDATA[Ku70 regulates Bax-mediated pathogenesis in laminin-{alpha}2-deficient human muscle cells and mouse models of congenital muscular dystrophy]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4477</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4467</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4478?rss=1">
<title><![CDATA[Lowe syndrome patient fibroblasts display Ocrl1-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4478?rss=1</link>
<description><![CDATA[
<p>The Lowe syndrome (LS) is a life-threatening, developmental disease characterized by mental retardation, cataracts and renal failure. Although this human illness has been linked to defective function of the phosphatidylinositol 5-phosphatase, Ocrl1 (<unl>O</unl>culo-<unl>C</unl>erebro-<unl>R</unl>enal syndrome of <unl>L</unl>owe protein <unl>1</unl>), the mechanism by which this enzyme deficiency triggers the disease is not clear. Ocrl1 is known to localize mainly to the Golgi apparatus and endosomes, however it translocates to plasma membrane ruffles upon cell stimulation with growth factors. The functional implications of this inducible translocation to the plasma membrane are presently unknown. Here we show that Ocrl1 is required for proper cell migration, spreading and fluid-phase uptake in both established cell lines and human dermal fibroblasts. We found that primary fibroblasts from two patients diagnosed with LS displayed defects in these cellular processes. Importantly, these abnormalities were suppressed by expressing wild-type Ocrl1 but not by a phosphatase-deficient mutant. Interestingly, the homologous human PI-5-phosphatase, Inpp5b, was unable to complement the Ocrl1-dependent cell migration defect. Further, Ocrl1 variants that cannot bind the endocytic adaptor AP2 or clathrin, like Inpp5b, were less apt to rescue the migration phenotype. However, no defect in membrane recruitment of AP2/clathrin or in transferrin endocytosis by patient cells was detected. Collectively, our results suggest that Ocrl1, but not Inpp5b, is involved in ruffle-mediated membrane remodeling. Our results provide new elements for understanding how Ocrl1 deficiency leads to the abnormalities associated with the LS.</p>
]]></description>
<dc:creator><![CDATA[Coon, B. G., Mukherjee, D., Hanna, C. B., Riese, D. J., Lowe, M., Aguilar, R. C.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp407</dc:identifier>
<dc:title><![CDATA[Lowe syndrome patient fibroblasts display Ocrl1-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4491</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4478</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4492?rss=1">
<title><![CDATA[X11{beta} rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4492?rss=1</link>
<description><![CDATA[
<p>Increased production and deposition of amyloid &beta;-protein (A&beta;) are believed to be key pathogenic events in Alzheimer's disease. As such, routes for lowering cerebral A&beta; levels represent potential therapeutic targets for Alzheimer's disease. X11&beta; is a neuronal adaptor protein that binds to the intracellular domain of the amyloid precursor protein (APP). Overexpression of X11&beta; inhibits A&beta; production in a number of experimental systems. However, whether these changes to APP processing and A&beta; production induced by X11&beta; overexpression also induce beneficial effects to memory and synaptic plasticity are not known. We report here that X11&beta;-mediated reduction in cerebral A&beta; is associated with normalization of both cognition and <I>in vivo</I> long-term potentiation in aged APPswe Tg2576 transgenic mice that model the amyloid pathology of Alzheimer's disease. Overexpression of X11&beta; itself has no detectable adverse effects upon mouse behaviour. These findings support the notion that modulation of X11&beta; function represents a therapeutic target for A&beta;-mediated neuronal dysfunction in Alzheimer's disease.</p>
]]></description>
<dc:creator><![CDATA[Mitchell, J. C., Ariff, B. B., Yates, D. M., Lau, K.-F., Perkinton, M. S., Rogelj, B., Stephenson, J. D., Miller, C. C.J., McLoughlin, D. M.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp408</dc:identifier>
<dc:title><![CDATA[X11{beta} rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4500</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4492</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4501?rss=1">
<title><![CDATA[Common fragile sites are characterized by histone hypoacetylation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4501?rss=1</link>
<description><![CDATA[
<p>Common fragile sites (CFSs) represent large, highly unstable regions of the human genome. CFS sequences are sensitive to perturbation of replication; however, the molecular basis for the instability at CFSs is poorly understood. We hypothesized that a unique epigenetic pattern may underlie the unusual sensitivity of CFSs to replication interference. To examine this hypothesis, we analyzed chromatin modification patterns within the six human CFSs with the highest levels of breakage, and their surrounding non-fragile regions (NCFSs). Chromatin at most of the CFSs analyzed has significantly less histone acetylation than that of their surrounding NCFSs. Trichostatin A and/or 5-azadeoxycytidine treatment reduced chromosome breakage at CFSs. Furthermore, chromatin at the most commonly expressed CFS, the FRA3B, is more resistant to micrococcal nuclease than that of the flanking non-fragile sequences. These results demonstrate that histone hypoacetylation is a characteristic epigenetic pattern of CFSs, and chromatin within CFSs might be relatively more compact than that of the NCFSs, indicating a role for chromatin conformation in genomic instability at CFSs. Moreover, lack of histone acetylation at CFSs may contribute to the defective response to replication stress characteristic of CFSs, leading to the genetic instability characteristic of this regions.</p>
]]></description>
<dc:creator><![CDATA[Jiang, Y., Lucas, I., Young, D. J., Davis, E. M., Karrison, T., Rest, J. S., Le Beau, M. M.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp410</dc:identifier>
<dc:title><![CDATA[Common fragile sites are characterized by histone hypoacetylation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4512</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4501</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4513?rss=1">
<title><![CDATA[An allergy-associated polymorphism in a novel regulatory element enhances IL13 expression]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4513?rss=1</link>
<description><![CDATA[
<p>IL-13 is a central effector of Th2-mediated allergic inflammation and is critical for the induction of IgE synthesis. Common <I>IL13</I> variants are associated with allergy phenotypes in populations of distinct ethnic background. We recently demonstrated that <I>IL13</I> expression by human CD4<sup>+</sup> T cells is paralleled by extensive <I>IL13</I> locus remodeling, which results in the appearance of multiple DNase I hypersensitive sites. Among these, HS4 in the distal promoter is constitutive in both na&iuml;ve and polarized Th1 and Th2 cells, and spans a common single nucleotide polymorphism, <I>IL13</I>-1512A&gt;C (rs1881457), strongly associated with total serum IgE levels. We recently characterized HS4 as a novel <I>cis</I>-acting element that upregulates <I>IL13</I> transcription in activated human and murine T cells. Here we show that <I>IL13</I>-1512A&gt;C is a functional polymorphism that significantly enhances HS4-dependent <I>IL13</I> expression by creating a binding site for the transcription factor Oct-1. Of note, endogenous Oct-1 was preferentially recruited to the <I>IL13</I>-1512C risk allele in primary CD4<sup>+</sup> T cells from <I>IL13</I>-1512A&gt;C heterozygous subjects. Moreover, the <I>IL13</I>-1512C allele was overexpressed in transfected Th2 cells from <I>Oct1</I><sup>+/+</sup> mice, but not from <I>Oct1</I><sup>+/&ndash;</sup> mice, demonstrating that increased activity was exquisitely dependent on physiologic levels of Oct-1. Our results illustrate how a functional variant in a regulatory element enhances transcription of an allergy-associated gene, thereby modulating disease susceptibility.</p>
]]></description>
<dc:creator><![CDATA[Kiesler, P., Shakya, A., Tantin, D., Vercelli, D.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp411</dc:identifier>
<dc:title><![CDATA[An allergy-associated polymorphism in a novel regulatory element enhances IL13 expression]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4520</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4513</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4521?rss=1">
<title><![CDATA[Functional analysis of 5-lipoxygenase promoter repeat variants]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4521?rss=1</link>
<description><![CDATA[
<p>Variants of a hexanucleotide repeat polymorphism in the promoter of the 5-lipoxygenase (<I><I>5-LO</I></I>) gene have been associated with cardiovascular disease traits in humans, which may be due, at least in part, to differential expression of the at-risk alleles. To more fully characterize these variants, we carried out gene expression and DNA methylation studies in primary leukocytes from healthy individuals carrying various <I><I>5-LO</I></I> promoter alleles. Regardless of genotype, <I><I>5-LO</I></I> and <I>5-LO</I>-activating protein (<I>FLAP</I>) gene expression was higher in granulocytes compared with monocytes and lymphocytes, whereas leukotriene A<SUB>4</SUB> hydrolase (<I>LTA4H</I>) expression was higher in monocytes. In all three leukocyte populations, <I>5-LO</I> mRNA levels were positively correlated with those of <I>FLAP</I> and <I>LTA4H</I>, with the highest correlation observed in granulocytes. In lymphocytes, individuals homozygous for the shorter 3 and 4 repeat alleles had between 20&ndash;35% higher <I>5-LO</I>, <I>FLAP</I> and <I>LTA4H</I> expression compared with homozygous carriers of the wild-type 5 repeat allele (<I>P</I> = 0.03&ndash;0.0001). DNA methylation analysis of four CpG islands in a 1500 bp region encompassing the <I>5-LO</I> promoter and the first ~100 bp of intron 1 revealed relatively low overall DNA methylation across all genotypes and leukocyte populations. However, analysis of the promoter repeats themselves demonstrated that, regardless of cell population, the 4 allele was methylated approximately twice as much as the 3 allele (<I>P</I> &lt; 0.0001). Our results demonstrate that, in lymphocytes, the shorter repeat alleles of the <I>5-LO</I> promoter lead to higher gene expression, which may be regulated through differential DNA methylation of the CpGs located within these repeats.</p>
]]></description>
<dc:creator><![CDATA[Vikman, S., Brena, R. M., Armstrong, P., Hartiala, J., Stephensen, C. B., Allayee, H.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp414</dc:identifier>
<dc:title><![CDATA[Functional analysis of 5-lipoxygenase promoter repeat variants]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4529</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4521</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4530?rss=1">
<title><![CDATA[The ocular albinism type 1 (OA1) G-protein-coupled receptor functions with MART-1 at early stages of melanogenesis to control melanosome identity and composition]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4530?rss=1</link>
<description><![CDATA[
<p>OA1 (GPR143; GPCR, G-protein-coupled receptor), the protein product of the ocular albinism type 1 gene, encodes a pigment-cell-specific GPCR that localizes intracellularly to melanosomes. OA1 mutations result in ocular albinism due to alterations in melanosome formation, suggesting that OA1 is a key player in the biogenesis of melanosomes. To address the function of OA1 in melanosome biogenesis, we have used siRNA inactivation and combined morphological and biochemical methods to investigate melanosome ultrastructure, melanosomal protein localization and expression in human pigmented melanocytic cells. OA1 loss of function leads to decreased pigmentation and causes formation of enlarged aberrant premelanosomes harboring disorganized fibrillar structures and displaying proteins of mature melanosomes and lysosomes at their membrane. Moreover, we show that OA1 interacts biochemically with the premelanosomal protein MART-1. Inactivation of MART-1 by siRNA leads to a decreased stability of OA1 and is accompanied by similar defects in premelanosome biogenesis and composition. These data show for the first time that melanosome composition and identity are regulated at early stages by OA1 and that MART-1 likely acts as an escort protein for this GPCR.</p>
]]></description>
<dc:creator><![CDATA[Giordano, F., Bonetti, C., Surace, E. M., Marigo, V., Raposo, G.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp415</dc:identifier>
<dc:title><![CDATA[The ocular albinism type 1 (OA1) G-protein-coupled receptor functions with MART-1 at early stages of melanogenesis to control melanosome identity and composition]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4545</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4530</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4546?rss=1">
<title><![CDATA[Pathogenic NAP57 mutations decrease ribonucleoprotein assembly in dyskeratosis congenita]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4546?rss=1</link>
<description><![CDATA[
<p>X-linked dyskeratosis congenita (DC) is a rare bone marrow failure syndrome caused by mostly missense mutations in the pseudouridine synthase NAP57 (dyskerin/Cbf5). As part of H/ACA ribonucleoproteins (RNPs), NAP57 is important for the biogenesis of ribosomes, spliceosomal small nuclear RNPs, microRNAs and the telomerase RNP. DC mutations concentrate in the N- and C-termini of NAP57 but not in its central catalytic domain raising questions as to their impact. We demonstrate that the N- and C-termini together form the binding surface for the H/ACA RNP assembly factor SHQ1 and that DC mutations modulate the interaction between the two proteins. Pinpointing impaired interaction between NAP57 and SHQ1 as a potential molecular basis for X-linked DC has implications for therapeutic approaches, e.g. by targeting the NAP57&ndash;SHQ1 interface with small molecules.</p>
]]></description>
<dc:creator><![CDATA[Grozdanov, P. N., Fernandez-Fuentes, N., Fiser, A., Meier, U. T.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp416</dc:identifier>
<dc:title><![CDATA[Pathogenic NAP57 mutations decrease ribonucleoprotein assembly in dyskeratosis congenita]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4551</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4546</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4552?rss=1">
<title><![CDATA[Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4552?rss=1</link>
<description><![CDATA[
<p>Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized by motor neuron degeneration. Mutations in Cu,Zn-superoxide dismutase (SOD1) are responsible for 20% of familial ALS cases via a toxic gain of function. In mutant SOD1 transgenic mice, mitochondria of spinal motor neurons develop abnormal morphology, bioenergetic defects and degeneration, which are presumably implicated in disease pathogenesis. SOD1 is mostly a cytosolic protein, but a substantial portion is associated with organelles, including mitochondria, where it localizes predominantly in the intermembrane space (IMS). However, whether mitochondrial mutant SOD1 contributes to disease pathogenesis remains to be elucidated. We have generated NSC34 motor neuronal cell lines expressing wild-type or mutant SOD1 containing a cleavable IMS targeting signal to directly investigate the pathogenic role of mutant SOD1 in mitochondria. We show that mitochondrially-targeted SOD1 localizes to the IMS, where it is enzymatically active. We prove that mutant IMS-targeted SOD1 causes neuronal toxicity under metabolic and oxidative stress conditions. Furthermore, we demonstrate for the first time neurite mitochondrial fragmentation and impaired mitochondrial dynamics in motor neurons expressing IMS mutant SOD1. These defects are associated with impaired maintenance of neuritic processes. Our findings demonstrate that mutant SOD1 localized in the IMS is sufficient to determine mitochondrial abnormalities and neuronal toxicity, and contributes to ALS pathogenesis.</p>
]]></description>
<dc:creator><![CDATA[Magrane, J., Hervias, I., Henning, M. S., Damiano, M., Kawamata, H., Manfredi, G.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp421</dc:identifier>
<dc:title><![CDATA[Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4564</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4552</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4565?rss=1">
<title><![CDATA[A mouse model for Meckel syndrome reveals Mks1 is required for ciliogenesis and Hedgehog signaling]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4565?rss=1</link>
<description><![CDATA[
<p>Meckel syndrome (MKS) is a rare autosomal recessive disease causing perinatal lethality associated with a complex syndrome that includes occipital meningoencephalocele, hepatic biliary ductal plate malformation, postaxial polydactyly and polycystic kidneys. The gene mutated in type 1 MKS encodes a protein associated with the base of the cilium in vertebrates and nematodes. However, shRNA knockdown studies in cell culture have reported conflicting results on the role of Mks1 in ciliogenesis. Here we show that loss of function of mouse <I>Mks1</I> results in an accurate model of human MKS, with structural abnormalities in the neural tube, biliary duct, limb patterning, bone development and the kidney that mirror the human syndrome. In contrast to cell culture studies, loss of <I>Mks1 in vivo</I> does not interfere with apical localization of epithelial basal bodies but rather leads to defective cilia formation in most, but not all, tissues. Analysis of patterning in the neural tube and the limb demonstrates altered Hedgehog (Hh) pathway signaling underlies some MKS defects, although both tissues show an expansion of the domain of response to Shh signaling, unlike the phenotypes seen in other mutants with cilia loss. Other defects in the skull, lung, rib cage and long bones are likely to be the result of the disruption of Hh signaling, and the basis of defects in the liver and kidney require further analysis. Thus the disruption of Hh signaling can explain many, but not all, of the defects caused by loss of Mks1.</p>
]]></description>
<dc:creator><![CDATA[Weatherbee, S. D., Niswander, L. A., Anderson, K. V.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp422</dc:identifier>
<dc:title><![CDATA[A mouse model for Meckel syndrome reveals Mks1 is required for ciliogenesis and Hedgehog signaling]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4575</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4565</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4576?rss=1">
<title><![CDATA[Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4576?rss=1</link>
<description><![CDATA[
<p>To understand the pathophysiology of neuropsychiatric disorders such as schizophrenia requires consideration of multiple genetic and non-genetic factors. However, very little is known about the consequences of combining models of synaptic dysfunction with controlled environmental manipulations. Therefore, to generate new insights into gene&ndash;environment interactions and complex behaviour, we examined the influence of variable prenatal stress (PNS) on two mouse lines with mutations in synaptosomal-associated protein of 25 kDa (Snap-25): the <I>blind-drunk</I> (<I>Bdr</I>) point mutant and heterozygous <I>Snap-25</I> knockout mice. Neonatal development was analysed in addition to an assessment of adult behavioural phenotypes relevant to the psychotic, cognitive and negative aspects of schizophrenia. These data show that PNS influenced specific anxiety-related behaviour in all animals. In addition, sensorimotor gating deficits previously noted in <I>Bdr</I> mutants were markedly enhanced by PNS; significantly, these effects could be reversed with the application of anti-psychotic drugs. Moreover, social interaction abnormalities were observed only in <I>Bdr</I> animals from stressed dams but not in wild-type littermates or mutants from non-stressed mothers. These results show for the first time that combining a synaptic mouse point mutant with a controlled prenatal stressor paradigm produces both modified and previously unseen phenotypes, generating new insights into the interactions between genetics and the environment relevant to the study of psychiatric disease.</p>
]]></description>
<dc:creator><![CDATA[Oliver, P. L., Davies, K. E.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp425</dc:identifier>
<dc:title><![CDATA[Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4589</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4576</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4590?rss=1">
<title><![CDATA[CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4590?rss=1</link>
<description><![CDATA[
<p>Mutations in the human X-linked cyclin-dependent kinase-like 5 (<I>CDKL5</I>) gene have been shown to cause severe neurodevelopmental disorders including infantile spasms, encephalopathy, West-syndrome and an early-onset variant of Rett syndrome. CDKL5 is a serine/threonine kinase whose involvement in Rett syndrome can be inferred by its ability to directly bind and mediate phosphorylation of MeCP2. However, it remains to be elucidated how CDKL5 exerts its function. Here, we report that CDKL5 localizes to specific nuclear foci referred to as nuclear speckles in both cell lines and tissues. These sub-nuclear structures are traditionally considered as storage/modification sites of pre-mRNA splicing factors. Interestingly, we provide evidence that CDKL5 regulates the dynamic behaviour of nuclear speckles. Indeed, CDKL5 overexpression leads to nuclear speckle disassembly, and this event is strictly dependent on its kinase activity. Conversely, its down-regulation affects nuclear speckle morphology leading to abnormally large and uneven speckles. Similar results were obtained for primary adult fibroblasts isolated from <I>CDKL5</I>-mutated patients. Altogether, these findings indicate that CDKL5 controls nuclear speckle morphology probably by regulating the phosphorylation state of splicing regulatory proteins. Nuclear speckles are dynamic sites that can continuously supply splicing factors to active transcription sites, where splicing occurs. Notably, we proved that CDKL5 influences alternative splicing, at least as proved in heterologous minigene assays. In conclusion, we provide evidence that CDKL5 is involved indirectly in pre-mRNA processing, by controlling splicing factor dynamics. These findings identify a biological process whose disregulation might affect neuronal maturation and activity in <I>CDKL5</I>-related disorders.</p>
]]></description>
<dc:creator><![CDATA[Ricciardi, S., Kilstrup-Nielsen, C., Bienvenu, T., Jacquette, A., Landsberger, N., Broccoli, V.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp426</dc:identifier>
<dc:title><![CDATA[CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4602</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4590</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4603?rss=1">
<title><![CDATA[Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4603?rss=1</link>
<description><![CDATA[
<p>Mutations in <I>SH3TC2</I> (<I>KIAA1985</I>) cause Charcot-Marie-Tooth disease (CMT) type 4C, a demyelinating inherited neuropathy characterized by early-onset and scoliosis. Here we demonstrate that the SH3TC2 protein is present in several components of the endocytic pathway including early endosomes, late endosomes and clathrin-coated vesicles close to the <I>trans</I>-Golgi network and in the plasma membrane. Myristoylation of SH3TC2 in glycine 2 is necessary but not sufficient for the proper location of the protein in the cell membranes. In addition to myristoylation, correct anchoring also needs the presence of SH3 and TPR domains. Mutations that cause a stop codon and produce premature truncations that remove most of the TPR domains are expressed as the wild-type protein. In contrast, missense mutations in or around the region of the first-TPR domain are absent from early endosomes, reduced in plasma membrane and late endosomes and are variably present in clathrin-coated vesicles. Our findings suggest that the endocytic and membrane trafficking pathway is involved in the pathogenesis of CMT4C disease. We postulate that missense mutations of <I>SH3TC2</I> could impair communication between the Schwann cell and the axon causing an abnormal myelin formation.</p>
]]></description>
<dc:creator><![CDATA[Lupo, V., Galindo, M. I., Martinez-Rubio, D., Sevilla, T., Vilchez, J. J., Palau, F., Espinos, C.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp427</dc:identifier>
<dc:title><![CDATA[Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4614</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4603</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4615?rss=1">
<title><![CDATA[Myosin VI is required for the proper maturation and function of inner hair cell ribbon synapses]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4615?rss=1</link>
<description><![CDATA[
<p>The ribbon synapses of auditory inner hair cells (IHCs) undergo morphological and electrophysiological transitions during cochlear development. Here we report that myosin VI (Myo6), an actin-based motor protein involved in genetic forms of deafness, is necessary for some of these changes to occur. By using post-embedding immunogold electron microscopy, we showed that Myo6 is present at the IHC synaptic active zone. In Snell's waltzer mutant mice, which lack Myo6, IHC ionic currents and ribbon synapse maturation proceeded normally until at least post-natal day 6. In adult mutant mice, however, the IHCs displayed immature potassium currents and still fired action potentials, as normally only observed in immature IHCs. In addition, the number of ribbons per IHC was reduced by 30%, and 30% of the remaining ribbons were morphologically immature. Ca<sup>2+</sup>-dependent exocytosis probed by capacitance measurement was markedly reduced despite normal Ca<sup>2+</sup> currents and the large proportion of morphologically mature synapses, which suggests additional defects, such as loose Ca<sup>2+</sup>-exocytosis coupling or inefficient vesicular supply. Finally, we provide evidence that Myo6 and otoferlin, a putative Ca<sup>2+</sup> sensor of synaptic exocytosis also involved in a genetic form of deafness, interact at the IHC ribbon synapse, and we suggest that this interaction is involved in the recycling of synaptic vesicles. Our findings thus uncover essential roles for Myo6 at the IHC ribbon synapse, in addition to that proposed in membrane turnover and anchoring at the apical surface of the hair cells.</p>
]]></description>
<dc:creator><![CDATA[Roux, I., Hosie, S., Johnson, S. L., Bahloul, A., Cayet, N., Nouaille, S., Kros, C. J., Petit, C., Safieddine, S.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp429</dc:identifier>
<dc:title><![CDATA[Myosin VI is required for the proper maturation and function of inner hair cell ribbon synapses]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4628</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4615</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4629?rss=1">
<title><![CDATA[GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4629?rss=1</link>
<description><![CDATA[
<p>Grb10-Interacting GYF Protein 2 (GIGYF2) was initially identified through its interaction with Grb10, an adapter protein that binds activated IGF-I and insulin receptors. The <I>GIGYF2</I> gene maps to human chromosome 2q37 within a region linked to familial Parkinson's disease (PARK11 locus), and association of <I>GIGYF2</I> mutations with Parkinson's disease has been described in some but not other recent publications. This study investigated the consequences of <I>Gigyf2</I> gene disruption in mice. <I>Gigyf2</I> null mice undergo apparently normal embryonic development, but fail to feed and die within the first 2 post-natal days. Heterozygous <I>Gigyf2</I><sup>+/&ndash;</sup> mice survive to adulthood with no evident metabolic or growth defects. At 12&ndash;15 months of age, the <I>Gigyf2</I><sup>+/&ndash;</sup> mice begin to exhibit motor dysfunction manifested as decreased balance time on a rotating horizontal rod. This is associated with histopathological evidence of neurodegeneration and rare intracytoplasmic Lewy body-like inclusions in spinal anterior horn motor neurons. There are -synuclein positive neuritic plaques in the brainstem and cerebellum, but no abnormalities in the substantia nigra. Primary cultured embryo fibroblasts from <I>Gigyf2</I> null mice exhibit decreased IGF-I-stimulated IGF-I receptor tyrosine phosphorylation and augmented ERK1/2 phosphorylation. These data provide further evidence for an important role of GIGYF2 in age-related neurodegeneration and IGF pathway signaling.</p>
]]></description>
<dc:creator><![CDATA[Giovannone, B., Tsiaras, W. G., de la Monte, S., Klysik, J., Lautier, C., Karashchuk, G., Goldwurm, S., Smith, R. J.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp430</dc:identifier>
<dc:title><![CDATA[GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4639</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4629</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4640?rss=1">
<title><![CDATA[Pharmacological activation of PPAR{beta}/{delta} stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4640?rss=1</link>
<description><![CDATA[
<p>A therapeutic strategy to treat Duchenne muscular dystrophy (DMD) involves identifying compounds that can elevate utrophin A expression in muscle fibers of affected patients. The dystrophin homologue utrophin A can functionally substitute for dystrophin when its levels are enhanced in the <I>mdx</I> mouse model of DMD. Utrophin A expression in skeletal muscle is regulated by mechanisms that promote the slow myofiber program. Since activation of peroxisome proliferator-activated receptor (PPAR) &beta;/ promotes the slow oxidative phenotype in skeletal muscle, we initiated studies to determine whether pharmacological activation of PPAR&beta;/ provides functional benefits to the <I>mdx</I> mouse. GW501516, a PPAR&beta;/ agonist, was found to stimulate utrophin A mRNA levels in C2C12 muscle cells through an element in the utrophin A promoter. Expression of PPAR&beta;/ was greater in skeletal muscles of <I>mdx</I> versus wild-type mice. We treated 5&ndash;7-week-old <I>mdx</I> mice with GW501516 for 4 weeks. This treatment increased the percentage of muscle fibers expressing slower myosin heavy chain isoforms and stimulated utrophin A mRNA levels leading to its increased expression at the sarcolemma. Expression of 1-syntrophin and &beta;-dystroglycan was restored to the sarcolemma. Improvement of <I>mdx</I> sarcolemmal integrity was evidenced by decreased intracellular IgM staining and decreased <I>in vivo</I> Evans blue dye (EBD) uptake. GW501516 treatment also conferred protection against eccentric contraction (ECC)-induced damage of <I>mdx</I> skeletal muscles, as shown by a decreased contraction-induced force drop and reduction of dye uptake during ECC. These results demonstrate that pharmacological activation of PPAR&beta;/ might provide functional benefits to DMD patients through enhancement of utrophin A expression.</p>
]]></description>
<dc:creator><![CDATA[Miura, P., Chakkalakal, J. V., Boudreault, L., Belanger, G., Hebert, R. L., Renaud, J.-M., Jasmin, B. J.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp431</dc:identifier>
<dc:title><![CDATA[Pharmacological activation of PPAR{beta}/{delta} stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4649</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4640</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4650?rss=1">
<title><![CDATA[A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4650?rss=1</link>
<description><![CDATA[
<p>Psychiatric disorders such as schizophrenia are commonly accompanied by cognitive impairments that are treatment resistant and crucial to functional outcome. There has been great interest in studying cognitive measures as endophenotypes for psychiatric disorders, with the hope that their genetic basis will be clearer. To investigate this, we performed a genome-wide association study involving 11 cognitive phenotypes from the Cambridge Neuropsychological Test Automated Battery. We showed these measures to be heritable by comparing the correlation in 100 monozygotic and 100 dizygotic twin pairs. The full battery was tested in ~750 subjects, and for spatial and verbal recognition memory, we investigated a further 500 individuals to search for smaller genetic effects. We were unable to find any genome-wide significant associations with either SNPs or common copy number variants. Nor could we formally replicate any polymorphism that has been previously associated with cognition, although we found a weak signal of lower than expected <I>P</I>-values for variants in a set of 10 candidate genes. We additionally investigated SNPs in genomic loci that have been shown to harbor rare variants that associate with neuropsychiatric disorders, to see if they showed any suggestion of association when considered as a separate set. Only <I>NRXN1</I> showed evidence of significant association with cognition. These results suggest that common genetic variation does not strongly influence cognition in healthy subjects and that cognitive measures do not represent a more tractable genetic trait than clinical endpoints such as schizophrenia. We discuss a possible role for rare variation in cognitive genomics.</p>
]]></description>
<dc:creator><![CDATA[Need, A. C., Attix, D. K., McEvoy, J. M., Cirulli, E. T., Linney, K. L., Hunt, P., Ge, D., Heinzen, E. L., Maia, J. M., Shianna, K. V., Weale, M. E., Cherkas, L. F., Clement, G., Spector, T. D., Gibson, G., Goldstein, D. B.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp413</dc:identifier>
<dc:title><![CDATA[A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4661</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4650</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4662?rss=1">
<title><![CDATA[Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4662?rss=1</link>
<description><![CDATA[
<p>Recently, associations of several common genetic variants with height have been reported in different populations. We attempted to identify further variants associated with adult height in a self-contained population (the Sorbs in Eastern Germany) as discovery set. We performed a genome wide association study (GWAS) (~390 000 genetic polymorphisms, Affymetrix gene arrays) on adult height in 929 Sorbian individuals. Subsequently, the best SNPs (<I>P</I> &lt; 0.001) were taken forward to a meta-analysis together with two independent cohorts [Diabetes Genetics Initiative, British 1958 Birth Cohort, (58BC, publicly available)]. Furthermore, we genotyped our best signal for replication in two additional German cohorts (Leipzig, <I>n</I> = 1044 and Berlin, <I>n</I> = 1728). In the primary Sorbian GWAS, we identified 5 loci with a <I>P</I>-value &lt; 10<sup>&ndash;5</sup> and 455 SNPs with <I>P</I>-value &lt; 0.001. In the meta-analysis on those 455 SNPs, only two variants in <I>GPR133</I> (rs1569019 and rs1976930; in LD with each other) retained a <I>P</I>-value at or below 10<sup>&ndash;6</sup> and were associated with height in the three cohorts individually. Upon replication, the SNP rs1569019 showed significant effects on height in the Leipzig cohort (<I>P</I> = 0.004, beta = 1.166) and in 577 men of the Berlin cohort (<I>P</I> = 0.049, beta = 1.127) though not in women. The combined analysis of all five cohorts (<I>n</I> = 6,687) resulted in a <I>P</I>-value of 4.7 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;8</sup> (beta = 0.949). In conclusion, our GWAS suggests novel loci influencing height. In view of the robust replication in five different cohorts, we propose <I>GPR133</I> to be a novel gene associated with adult height.</p>
]]></description>
<dc:creator><![CDATA[Tonjes, A., Koriath, M., Schleinitz, D., Dietrich, K., Bottcher, Y., Rayner, N. W., Almgren, P., Enigk, B., Richter, O., Rohm, S., Fischer-Rosinsky, A., Pfeiffer, A., Hoffmann, K., Krohn, K., Aust, G., Spranger, J., Groop, L., Bluher, M., Kovacs, P., Stumvoll, M.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp423</dc:identifier>
<dc:title><![CDATA[Genetic variation in GPR133 is associated with height: genome wide association study in the self-contained population of Sorbs]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4668</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4662</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4669?rss=1">
<title><![CDATA[Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4669?rss=1</link>
<description><![CDATA[
<p>Adiponutrin (<I>PNPLA3</I>) is a predominantly liver-expressed transmembrane protein with phospholipase activity that is regulated by fasting and feeding. Recent genome-wide association studies identified <I>PNPLA3</I> to be associated with hepatic fat content and liver function, thus pointing to a possible involvement in the hepatic lipoprotein metabolism. The aim of this study was to examine the association between two common variants in the adiponutrin gene and parameters of lipoprotein metabolism in 23 274 participants from eight independent West-Eurasian study populations including six population-based studies [Bruneck (<I>n</I> = 800), KORA S3/F3 (<I>n</I> = 1644), KORA S4/F4 (<I>n</I> = 1814), CoLaus (<I>n</I> = 5435), SHIP (<I>n</I> = 4012), Rotterdam (<I>n</I> = 5967)], the SAPHIR Study as a healthy working population (<I>n</I> = 1738) and the Utah Obesity Case-Control Study including a group of 1037 severely obese individuals (average BMI 46 kg/m<sup>2</sup>) and 827 controls from the same geographical region of Utah. We observed a strong additive association of a common non-synonymous variant within adiponutrin (rs738409) with age-, gender-, and alanine-aminotransferase-adjusted lipoprotein concentrations: each copy of the minor allele decreased levels of total cholesterol on average by 2.43 mg/dl (<I>P</I> = 8.87 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;7</sup>), non-HDL cholesterol levels by 2.35 mg/dl (<I>P</I> = 2.27 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;6</sup>) and LDL cholesterol levels by 1.48 mg/dl (<I>P</I> = 7.99 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;4</sup>). These associations remained significant after correction for multiple testing. We did not observe clear evidence for associations with HDL cholesterol or triglyceride concentrations. In conclusion, our study suggests that adiponutrin is involved in the metabolism of apoB-containing lipoproteins.</p>
]]></description>
<dc:creator><![CDATA[Kollerits, B., Coassin, S., Beckmann, N. D., Teumer, A., Kiechl, S., Doring, A., Kavousi, M., Hunt, S. C., Lamina, C., Paulweber, B., Kutalik, Z., Nauck, M., van Duijn, C. M., Heid, I. M., Willeit, J., Brandstatter, A., Adams, T. D., Mooser, V., Aulchenko, Y. S., Volzke, H., Kronenberg, F.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp424</dc:identifier>
<dc:title><![CDATA[Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4676</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4669</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4677?rss=1">
<title><![CDATA[Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4677?rss=1</link>
<description><![CDATA[
<p>Low plasma B-vitamin levels and elevated homocysteine have been associated with cancer, cardiovascular disease and neurodegenerative disorders. Common variants in <I>FUT2</I> on chromosome 19q13 were associated with plasma vitamin B<SUB>12</SUB> levels among women in a genome-wide association study in the Nurses&rsquo; Health Study (NHS) NCI-Cancer Genetic Markers of Susceptibility (CGEMS) project. To identify additional loci associated with plasma vitamin B<SUB>12</SUB>, homocysteine, folate and vitamin B<SUB>6</SUB> (active form pyridoxal 5'-phosphate, PLP), we conducted a meta-analysis of three GWA scans (total <I>n</I> = 4763, consisting of 1658 women in NHS-CGEMS, 1647 women in Framingham-SNP-Health Association Resource (SHARe) and 1458 men in SHARe). On chromosome 19q13, we confirm the association of plasma vitamin B<SUB>12</SUB> with rs602662 and rs492602 (<I>P</I>-value = 1.83 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;15</sup> and 1.30 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;14</sup>, respectively) in strong linkage disequilibrium (LD) with rs601338 (<I>P</I> = 6.92 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;15</sup>), the <I>FUT2 W143X</I> nonsense mutation. We identified additional genome-wide significant loci for plasma vitamin B<SUB>12</SUB> on chromosomes 6p21 (<I>P</I> = 4.05 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;08</sup>), 10p12 (<I>P</I>-value=2.87 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;9</sup>) and 11q11 (<I>P</I>-value=2.25 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;10</sup>) in genes with biological relevance. We confirm the association of the well-studied functional candidate SNP 5,10-<I>methylene tetrahydrofolate reductase (MTHFR) Ala222Val</I> (dbSNP ID: rs1801133; <I>P</I>-value=1.27 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;8</sup>), on chromosome 1p36 with plasma homocysteine and identify an additional genome-wide significant locus on chromosome 9q22 (<I>P</I>-value=2.06 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;8</sup>) associated with plasma homocysteine. We also identified genome-wide associations with variants on chromosome 1p36 with plasma PLP (<I>P</I>-value=1.40 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;15</sup>). Genome-wide significant loci were not identified for plasma folate. These data reveal new biological candidates and confirm prior candidate genes for plasma homocysteine, plasma vitamin B<SUB>12</SUB> and plasma PLP.</p>
]]></description>
<dc:creator><![CDATA[Hazra, A., Kraft, P., Lazarus, R., Chen, C., Chanock, S. J., Jacques, P., Selhub, J., Hunter, D. J.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp428</dc:identifier>
<dc:title><![CDATA[Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4687</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4677</prism:startingPage>
<prism:section>ASSOCIATION STUDIES ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/18/23/4688?rss=1">
<title><![CDATA[An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/18/23/4688?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Deguara, J., Burnand, K. G., Berg, J., Green, P., Lewis, C. M., Chinien, G., Waltham, M., Taylor, P., Stern, R. F., Solomon, E., Smith, A.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 06:02:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddp439</dc:identifier>
<dc:title><![CDATA[An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>23</prism:number>
<prism:volume>18</prism:volume>
<prism:endingPage>4688</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>4688</prism:startingPage>
<prism:section>CORRIGENDUM</prism:section>
</item>

</rdf:RDF>